Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Miguel Gil-Gil
Real-World Efficacy and Safety of Eribulin in Advanced and Pretreated HER2-negative Breast Cancer in a Spanish Comprehensive Cancer Center
BMC pharmacology & toxicology
Medicine
Pharmacology
Related publications
Eribulin in Pretreated Metastatic Breast Cancer Patients: Results of the TROTTER Trial—a Multicenter Retrospective Study of Eribulin in Real Life
SpringerPlus
Multidisciplinary
Breast Cancer Stem Cells in HER2-negative Breast Cancer Cells Contribute to HER2-mediated Radioresistance and Molecular Subtype Conversion: Clinical Implications for Serum HER2 in Recurrent HER2-negative Breast Cancer
Oncotarget
Oncology
Real-World Patient- And Caregiver-Reported Outcomes in Advanced Breast Cancer
Current Oncology
Oncology
Olaparib in the Therapy of Advanced Ovarian Cancer: First Real World Experiences in Safety and Efficacy From China
Journal of Ovarian Research
Gynecology
Oncology
Obstetrics
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Geburtshilfe und Frauenheilkunde
Gynecology
Midwifery
Maternity
Obstetrics
Real-World Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis
Scientific Reports
Multidisciplinary
Efficacy and Safety of HER2-Targeted Agents for Breast Cancer With HER2-Overexpression: A Network Meta-Analysis
PLoS ONE
Multidisciplinary
Eribulin for the Treatment of Metastatic Breast Cancer: An Update on Its Safety and Efficacy
International Journal of Women's Health
Gynecology
Oncology
Midwifery
Maternity
Obstetrics
Use of Eribulin as an Earlier-Line Chemotherapy for Patients With HER2-negative Metastatic Breast Cancer
Journal of Cancer
Oncology
